Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 40 14
Bone Carcinoma 12 14 69
Malignant Bone Neoplasm 12 69
Bone Neoplasms 41 69
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 69
Osteogenic Neoplasm 69
Ca - Bone Cancer 12
Neoplasm of Bone 12
Bone Neoplasm 12
Osseous Tumor 12
Bone Tumour 12

Classifications:



Summaries for Bone Cancer

MedlinePlus : 40 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as bone carcinoma, is related to bone squamous cell carcinoma and ewing sarcoma, and has symptoms including sciatica, muscle cramp and back pain. An important gene associated with Bone Cancer is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are ERK Signaling and Development Endothelin-1/EDNRA signaling. The drugs Quadramet and Xgeva have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and breast, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A bone cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Related Diseases for Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 bone squamous cell carcinoma 31.2 CDKN2A ENG RLN2
2 ewing sarcoma 30.9 CDKN2A CYCS ENG EWSR1 IL6 MMP9
3 osteoporosis 29.3 COL1A1 IL6 TNFRSF11A TNFSF11 TRPV1
4 myeloma, multiple 29.1 CDKN2A IL6 TNFSF11
5 chest wall bone cancer 12.0
6 primary bone cancer 12.0
7 bone marrow cancer 11.2
8 maxillary neoplasm 10.8
9 osteogenic sarcoma 10.8
10 chondrosarcoma 10.6
11 multiple enchondromatosis, maffucci type 10.6
12 bone fracture 10.6
13 long bones of lower limb cancer 10.6
14 jaw cancer 10.6
15 orbital cancer 10.6
16 bone giant cell tumor 10.6
17 sternum cancer 10.6
18 paget's disease of bone 10.6
19 femoral cancer 10.6
20 bone lymphoma 10.6
21 polyarticular onset juvenile idiopathic arthritis 10.6 TNFRSF11A TNFSF11
22 breast leiomyosarcoma 10.6 TNFRSF11A TNFSF11
23 hemophilic arthropathy 10.5 TNFRSF11A TNFSF11
24 paget disease of bone 5, juvenile-onset 10.5 TNFRSF11A TNFSF11
25 osteoporotic fracture 10.5 COL1A1 IL6
26 bone remodeling disease 10.5 TNFRSF11A TNFSF11 TRPV1
27 root resorption 10.5 P2RX7 TNFRSF11A TNFSF11
28 mouth disease 10.5 IL6 TNFSF11 TRPV1
29 periodontitis, chronic 10.5 IL6 TNFSF11
30 episodic pain syndrome, familial, 1 10.4
31 periapical periodontitis 10.4 MMP9 TNFRSF11A TNFSF11
32 rosacea 10.4 IL6 MMP9 TRPV1
33 villonodular synovitis 10.4 MMP9 TNFSF11
34 overnutrition 10.4 CCL2 IL6 TRPV1
35 connective tissue cancer 10.4 COL1A1 EWSR1 TRPV1
36 diabetic foot ulcers 10.4 IL6 MMP9
37 giant cell tumor 10.4 MMP9 TNFRSF11A TNFSF11
38 urinary system disease 10.4 CCL2 IL6 TRPV1
39 radiculopathy 10.4 CCL2 IL6 PENK
40 spinal cord injury 10.4 IL6 MMP9 PDYN
41 breast adenocarcinoma 10.3 CYCS MMP9 TNFSF11
42 acute transverse myelitis 10.3 IL6 MMP9
43 acquired metabolic disease 10.3 CCL2 IL6 TRPV1
44 bone inflammation disease 10.3 CCL2 IL6 TNFSF11 TRPV1
45 familial expansile osteolysis 10.3 TNFRSF11A TNFSF11
46 chorioamnionitis 10.3 CCL2 IL6 MMP9
47 aortic aneurysm, familial abdominal, 1 10.3 CCL2 IL6 MMP9
48 relapsing-remitting multiple sclerosis 10.3 CCL2 IL6 MMP9
49 dissociative amnesia 10.3 PDYN TNFSF11
50 periodontal disease 10.3 IL6 MMP9 TNFRSF11A TNFSF11

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:


sciatica, muscle cramp, back pain

MGI Mouse Phenotypes related to Bone Cancer:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 ATF3 CDKN2A COL1A1 CYCS ENG IL6
2 growth/size/body region MP:0005378 10.27 ATF3 CDKN2A COL1A1 CYCS ENG IL6
3 cardiovascular system MP:0005385 10.19 CDKN2A COL1A1 CYCS ENG IL6 MMP9
4 homeostasis/metabolism MP:0005376 10.18 COL1A1 ENG IL6 ATF3 CDKN2A MMP9
5 immune system MP:0005387 10.18 ATF3 CCL2 CDKN2A COL1A1 CYCS IL6
6 hematopoietic system MP:0005397 10.17 ATF3 CDKN2A COL1A1 CYCS ENG IL6
7 integument MP:0010771 10.1 ATF3 CDKN2A COL1A1 ENG IL6 MMP9
8 digestive/alimentary MP:0005381 10.02 CDKN2A COL1A1 ENG IL6 MMP9 PDYN
9 neoplasm MP:0002006 9.86 TNFSF11 TRPV1 ATF3 CDKN2A COL1A1 IL6
10 no phenotypic analysis MP:0003012 9.76 PDYN PENK TNFRSF11A TNFSF11 TRPV1 ATF3
11 respiratory system MP:0005388 9.61 ATF3 CDKN2A COL1A1 ENG IL6 MMP9
12 skeleton MP:0005390 9.32 CDKN2A COL1A1 CYCS IL6 MMP9 P2RX7

Drugs & Therapeutics for Bone Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Quadramet 17 SAMARIUM SM-153 LEXIDRONAM PENTASODIUM DuPont Merck Pharmaceutical Company March 1997
2
Xgeva 17 45 DENOSUMAB Amgen June 2013/ November 2010
3
Xofigo 17 45 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
4
Zometa 17 45 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 430)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
2
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
3
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
6
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
7
Radium Ra 223 dichloride Approved, Investigational Phase 4,Phase 2,Phase 1 444811-40-9
8
Dalteparin Approved Phase 4 9005-49-6
9
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
12
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 1406-16-2
13
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
14 Anesthetics Phase 4,Phase 3,Phase 1
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
17 Cortisol succinate Phase 4
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
19 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20 Hormones Phase 4,Phase 3,Phase 2,Phase 1
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Hydrocortisone 17-butyrate 21-propionate Phase 4
23 Hydrocortisone acetate Phase 4
24 Hydrocortisone-17-butyrate Phase 4
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Diphosphonates Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Calcium, Dietary Phase 4,Phase 1,Phase 2
29 Vitamins Phase 4,Phase 2,Phase 1
30 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
31 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
33 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Adrenergic Agents Phase 4
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Central Nervous System Stimulants Phase 4,Phase 2,Phase 1
37 Dopamine Agents Phase 4,Phase 2
38 Dopamine Uptake Inhibitors Phase 4
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Neurotransmitter Uptake Inhibitors Phase 4
41 Ibandronic acid Phase 4,Phase 3,Phase 2
42 Central Nervous System Depressants Phase 4,Phase 3,Phase 1
43 Cyclooxygenase Inhibitors Phase 4,Phase 2
44 Antidepressive Agents Phase 4
45 Antimanic Agents Phase 4,Phase 1
46 Lithium carbonate Phase 4 554-13-2
47 Psychotropic Drugs Phase 4,Phase 1
48 Tranquilizing Agents Phase 4,Phase 1
49 Anticoagulants Phase 4
50 calcium heparin Phase 4

Interventional clinical trials:

(show top 50) (show all 698)

# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
3 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
4 Bioactive Glass Granules in Filling of Bone Defects Completed NCT01304121 Phase 4
5 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
6 A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer Completed NCT02553707 Phase 4 Ibandronate
7 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
8 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
9 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
10 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
11 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
12 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
13 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
14 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
15 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
16 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Recruiting NCT03301857 Phase 4 Cohort A Denosumab
17 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Recruiting NCT02905916 Phase 4 PEG-rhG-CSF
18 Radium-223 Dichloride Long-term Follow-up Program Active, not recruiting NCT02312960 Phase 4
19 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Not yet recruiting NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
20 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
21 A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer Terminated NCT00381095 Phase 4 Pregabalin;Placebo
22 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
23 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
24 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Unknown status NCT01091883 Phase 3
25 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
26 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
27 Non-invasive Focal Therapy for Osteoid Osteoma Unknown status NCT02302651 Phase 2, Phase 3
28 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases Unknown status NCT01429493 Phase 2, Phase 3
29 F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Unknown status NCT00882609 Phase 3
30 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
31 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
32 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
33 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
34 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3 Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
35 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3 High Dose Methotrexate
36 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3 pre-surgical chemotherapy
37 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
38 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
39 ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain Completed NCT00656305 Phase 3
40 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
41 A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
42 A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease Completed NCT02561039 Phase 3 Ibandronate
43 Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy Completed NCT00041665 Phase 3 Recombinant Human Keratinocyte Growth Factor
44 Dynamic Magnetic Resonance (MR) Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research Completed NCT00172224 Phase 3
45 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
46 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
47 Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009 Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
48 Palliation: the Effect of Education on Pain Completed NCT01358539 Phase 3
49 Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
50 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

MalaCards organs/tissues related to Bone Cancer:

38
Bone, Prostate, Breast, Lung, Brain, T Cells, Spinal Cord

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 178)
# Title Authors Year
1
Adverse events associated with aprepitant pediatric bone cancer patients. ( 29409391 )
2018
2
IL-18 Contributes to Bone Cancer Pain by Regulating Glia Cells and Neuron Interaction. ( 29079540 )
2018
3
Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway. ( 29096563 )
2018
4
Socio-economic patterning in early mortality of patients aged 0-49 years diagnosed with primary bone cancer in Great Britain, 1985-2008. ( 29414632 )
2018
5
Longitudinal resting-state fMRI in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state. ( 29319607 )
2018
6
Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. ( 29357732 )
2018
7
Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulation of the Akt/ERK signaling pathway in mice. ( 29395120 )
2018
8
A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain. ( 29371114 )
2018
9
Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. ( 29127069 )
2018
10
Spinal PKC activation - Induced neuronal HMGB1 translocation contributes to hyperalgesia in a bone cancer pain model in rats. ( 29428215 )
2018
11
DNMT3a contributes to the development and maintenance of bone cancer pain by silencing Kv1.2 expression in spinal cord dorsal horn. ( 29056068 )
2017
12
Multicenter experiences in temporal bone cancer surgery based on 89 cases. ( 28225795 )
2017
13
Normalizing GDNF expression in the spinal cord alleviates cutaneous hyperalgesia but not ongoing pain in a rat model of bone cancer pain. ( 27716965 )
2017
14
Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. ( 28484877 )
2017
15
Multi-target treatment of bone cancer pain using synergistic combinations of pharmacological compounds in experimental animals. ( 28850433 )
2017
16
Spinal miRNA-124 regulates synaptopodin and nociception in an animal model of bone cancer pain. ( 28887457 )
2017
17
Efficacy and mechanism of action of etanercept in bone cancer pain. ( 29441991 )
2017
18
The Molecular Genetic Expression as a Novel Biomarker in the Evaluation and Monitoring of Patients With Osteosarcoma-Subtype Bone Cancer Disease. ( 28425009 )
2017
19
Morin Suppresses Astrocyte Activation and Regulates Cytokine Release in Bone Cancer Pain Rat Models. ( 28618070 )
2017
20
STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. ( 27742579 )
2017
21
Simultaneous inhibition of NMDA and mGlu1/5 receptors by levo-corydalmine in rat spinal cord attenuates bone cancer pain. ( 28500623 )
2017
22
Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain. ( 28286408 )
2017
23
Vincristine-loaded hydroxyapatite nanoparticles as a potential delivery system for bone cancer therapy. ( 29098881 )
2017
24
Alleviating Mechanical Allodynia and Modulating Cellular Immunity Contribute to Electroacupuncture's Dual Effect on Bone Cancer Pain. ( 28870114 )
2017
25
Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor. ( 28825192 )
2017
26
The analgesic effects of triptolide in the bone cancer pain rats via inhibiting the upregulation of HDACs in spinal glial cells. ( 29096654 )
2017
27
Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. ( 29300279 )
2017
28
Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer. ( 29234825 )
2017
29
Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. ( 28565880 )
2017
30
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring I1-opioid receptor in spinal cord. ( 28559159 )
2017
31
Recombinant protein transduction domain-Cu/Zn superoxide dismutase alleviates bone cancer pain via peroxiredoxin 4 modulation and antioxidation. ( 28391978 )
2017
32
Analgesic effects of microRNA-129-5p against bone cancer pain through the EphB1/EphrinB2 signaling pathway in mice. ( 29236320 )
2017
33
Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. ( 28840279 )
2017
34
Upregulation of Spinal Voltage-Dependent Anion Channel 1 Contributes to Bone Cancer Pain Hypersensitivity in Rats. ( 29196874 )
2017
35
Bone cancer: Is the osteosarcoma genome targetable? ( 28776583 )
2017
36
Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats. ( 27841001 )
2017
37
Plasma-induced selectivity in bone cancer cells death. ( 28571751 )
2017
38
Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy. ( 29036449 )
2017
39
Hyperthermia effect and antibacterial efficacy of Fe(3+) /Co(2+) co-substitutions in I^-Ca3 (PO4 )2 for bone cancer and defect therapy. ( 28661574 )
2017
40
Effect of alkylaminophenols on growth inhibition and apoptosis of bone cancer cells. ( 28728976 )
2017
41
Neuron-restrictive silencer factor-mediated downregulation of I1-opioid receptor contributes to the reduced morphine analgesia in bone cancer pain. ( 28415063 )
2017
42
Retraction Statement: CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. ( 28417467 )
2017
43
siRNA-mediated downregulation of GluN2B in the rostral anterior cingulate cortex attenuates mechanical allodynia and thermal hyperalgesia in a rat model of pain associated with bone cancer. ( 26889244 )
2016
44
Evaluation of Bone Cancer Pain Induced by Different Doses of Walker 256 Mammary Gland Carcinoma Cells. ( 27676678 )
2016
45
The perceptions of teenagers, young adults and professionals in the participation of bone cancer clinical trials. ( 26936110 )
2016
46
MicroRNA-93-5p may participate in the formation of morphine tolerance in bone cancer pain mouse model by targeting Smad5. ( 27438143 )
2016
47
GPR30 disrupts the balance of GABAergic and glutamatergic transmission in the spinal cord driving to the development of bone cancer pain. ( 27608844 )
2016
48
Silencing Transient Receptor Potential Vanilloid Receptor Subtype I-Containing Sensory Neurons to Treat Bone Cancer Pain. ( 27176213 )
2016
49
Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain. ( 27275127 )
2016
50
Dissociation between the relief of skeletal pain behaviors and skin hypersensitivity in a model of bone cancer pain. ( 27186713 )
2016

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Pathways for Bone Cancer

GO Terms for Bone Cancer

Cellular components related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 ENG P2RX7 TNFRSF11A TRPV1

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.91 CCL2 IL6 P2RX7 TNFRSF11A TRPV1
2 positive regulation of apoptotic process GO:0043065 9.88 CDKN2A IL6 MMP9 P2RX7 TRPV1
3 regulation of receptor activity GO:0010469 9.85 CCL2 IL6 PDYN PENK RLN2 TNFSF11
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 IL6 TNFRSF11A TNFSF11 TRIM14
5 osteoblast differentiation GO:0001649 9.75 COL1A1 MRC2 PENK
6 collagen catabolic process GO:0030574 9.71 COL1A1 MMP9 MRC2
7 positive regulation of DNA binding transcription factor activity GO:0051091 9.71 IL6 TNFRSF11A TNFSF11 TRIM14
8 sensory perception of pain GO:0019233 9.67 P2RX7 PENK TRPV1
9 sensory perception GO:0007600 9.57 PDYN PENK
10 negative regulation of bone resorption GO:0045779 9.56 IL6 P2RX7
11 PERK-mediated unfolded protein response GO:0036499 9.55 ATF3 CCL2
12 response to corticosteroid GO:0031960 9.52 COL1A1 ENG
13 ossification GO:0001503 9.46 COL1A1 MMP9 TNFRSF11A TNFSF11
14 TNFSF11-mediated signaling pathway GO:0071847 9.43 TNFRSF11A TNFSF11
15 positive regulation of gene expression GO:0010628 9.43 ATF3 CDKN2A ENG IL6 P2RX7 RLN2
16 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.32 TNFRSF11A TNFSF11
17 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.26 TNFRSF11A TNFSF11
18 monocyte chemotaxis GO:0002548 8.92 CCL2 IL6 TNFRSF11A TNFSF11

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.46 ENG MRC2 TNFRSF11A TRPV1
2 opioid receptor binding GO:0031628 8.96 PDYN PENK
3 opioid peptide activity GO:0001515 8.62 PDYN PENK

Sources for Bone Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....